Oxime substituted therapeutic compounds

Details Oxime substituted therapeutic compounds Oxime substituted therapeutic compounds

1994-02-07

1998-06-23

MacMillan, Keith

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

544271, 544273, M61K 3152

Patent

active

057705950

ABSTRACT:
Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula:

REFERENCES:
patent: 3422107 (1969-01-01), Mohler et al.
patent: 3737433 (1973-06-01), Mohler et al.
patent: 4515795 (1985-05-01), Hinze et al.
patent: 4576947 (1986-03-01), Hinze et al.
patent: 4636507 (1987-01-01), Kreutzer et al.
patent: 4833146 (1989-05-01), Gebert et al.
patent: 4965271 (1990-10-01), Mandell et al.
patent: 5039666 (1991-08-01), Novick et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5112827 (1992-05-01), Suander et al.
patent: 5118500 (1992-06-01), Hanel et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: 5354756 (1994-10-01), Underiner et al.
patent: 5470878 (1995-11-01), Michnick et al.
patent: 5473070 (1995-12-01), Underiner et al.
patent: 5521315 (1996-05-01), Underiner et al.
patent: B13737433 (1987-03-01), Mohler et al.
Chemical Abstract AN 115: 280052, Fraisse et al, EP 447324 A1, Sep. 18, 1991, Abstract Only.
Chemical Abstracts, AN 1969:37788, Zackowska et al, May 1969.
Chemical Abstracts, AN 1977:55392, Werner et al, Aug. 1976.
Chemical Abstracts, AN 1977:165145, Kokel et al, Nov. 1976.
CA 86:165145, Kokel et al, "Antiviral Properties of Theophylline Derivatives", Eur. J. Med. Chem vol. 11(6), pp. 527-532, 1976. Abstract Only.
CA 70:37788, Zajaczkowska et al, "The Search for New drugs in the Group of Xanthine Derivatives", Diss. Pharm. Pharmacol., vol. 20(5), pp. 497-505, 1968. Abstract only.
Chem Abst 53: 11394(F) 1959.
Chem Abst. 70: 37788 1968.
Chem Abst. 51: 1204 (F) 1957.
Bianco et al., Blood, 76:Supplement 1 (522), p. 133a, "Pentoxifylline (PTX) and GM-CSF Decrease Tumor Necrosis Factor-ALPHA (TNF-.alpha.) Levels in Patients Undergoing Allogeneic Bone Marrow Transplantation (BMT)," 1991.
Davis et al., Applied Environment Microbial., 48:2, pp. 327-331, "Microbial Models of Mammalian Metabolism: Microbial Reduction and Oxidation of Pentoxifylline," Aug. 1984.
Bursten et al., The Journal of Biological Chemistry, vol. 266, No. 31, pp. 20732-20743, "Interleukin-1 Rapidly Stimulates Lysophosphatidate Acyltransferase and Phosphatidate Phosphohydrolase Activities in Human Mesangial Cells", 1991.
Drabczynska et al., Pol. J. Pharmacol. Pharm., vol. 28, pp. 95-103, "The Search for New Drugs in the Group of Xanthine Derivaties", 1976.
Epstein et al., The New England Journal of Medicine, vol. 328, No. 2, pp. 106-113, "The Role of Interleukin-1 in Disease", 1993.
Goodman et al., Macmillan Publishing Company, Inc. (New York), pp. 1-46, "The Pharmacological Basis of Therapeutics", 1975.

Affiliated with

Also associated with

Rating

Oxime substituted therapeutic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oxime substituted therapeutic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxime substituted therapeutic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1394950